Mizuho
Exact Sciences Stock Downgraded in Wake of Q1 Earnings Report
Mizuho Securities has lowered its rating of the company to Neutral from Buy and cut the price target on its stock nearly in half to $6.50 from $12.
Investment Banks Downgrade Bruker on Resignation of CFO
Mizuho and William Blair downgraded Bruker, following the resignation of CFO Charles Wagner, who was noted for his role in implementing a turnaround at the company.
Piper Jaffray, Mizuho Initiate Coverage of CareDx with Bullish Outlooks
NEW YORK (GenomeWeb) – Piper Jaffray and Mizuho Securities today initiated coverage of transplant molecular diagnostics firm CareDx with bullish views of the company's stock and market opportunities for its tests.
Mizuho Upgrades Fluidigm Shares to Buy
NEW YORK (GenomeWeb) – Investment bank Mizuho Securities has upgraded shares of Fluidigm from Neutral to Buy citing improved end markets and the expected effects from the firm's recent acquisition of DVS Sciences.
Mizuho Upgrades Myriad, Citing Medicare Reimbursement and 'Overstated' Competitive Pressures
NEW YORK (GenomeWeb News) – Mizuho Securities today upgraded shares of Myriad Genetics to a Buy rating, citing an increase in Medicare reimbursements for the BRACAnalysis test, as well as stabilized competition, and several potential positive catalysts over the next year to 24 months.
Jan 22, 2013
Mizuho Downgrades BD to Neutral
Nov 16, 2012
Mizuho Upgrades Cepheid to Buy
Jul 31, 2012
May 21, 2012
Mizuho Upgrades Waters on Improving Pharma Picture
Jan 17, 2012